Barinthus Biotherapeutics plc
BRNS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,150 | $6,611 | $7,988 | $6,222 |
| G&A Expenses | $5,165 | $15,384 | $12,639 | $3,055 |
| SG&A Expenses | $5,165 | $15,384 | $12,639 | $3,055 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,751 | $1,329 | -$27 | $14,113 |
| Operating Expenses | $15,066 | $23,324 | $20,600 | $23,390 |
| Operating Income | -$15,066 | -$23,324 | -$20,600 | -$23,390 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $424 | $2,173 | $920 | $2,802 |
| Pre-Tax Income | -$14,642 | -$21,151 | -$19,680 | -$20,588 |
| Tax Expense | -$71 | -$25 | -$22 | $3 |
| Net Income | -$14,566 | -$21,124 | -$19,648 | -$20,540 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.52 | -0.49 | -0.51 |
| % Growth | 30.8% | -6.1% | 3.9% | – |
| EPS Diluted | -0.36 | -0.52 | -0.49 | -0.51 |
| Weighted Avg Shares Out | 40,661 | 40,344 | 40,265 | 39,348 |
| Weighted Avg Shares Out Dil | 40,661 | 40,344 | 40,265 | 39,348 |
| Supplemental Information | – | – | – | – |
| Interest Income | $472 | $523 | $556 | $637 |
| Interest Expense | $13 | $12 | $13 | $12 |
| Depreciation & Amortization | $1,201 | $2,001 | $2,034 | $1,428 |
| EBITDA | -$13,428 | -$19,138 | -$17,633 | -$19,148 |
| % Margin | – | – | – | – |